IP Verse

Compositions And Methods For The Treatment Of Infections And Tumors - EP2133365

The patent EP2133365 was granted to Dana Farber Cancer Institute on May 17, 2017. The application was originally filed on Dec 26, 2007 under application number EP09166886A. The patent is currently recorded with a legal status of "Revoked".

EP2133365

DANA FARBER CANCER INSTITUTE
Application Number
EP09166886A
Filing Date
Dec 26, 2007
Status
Revoked
Aug 12, 2022
Grant Date
May 17, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PFIZERFeb 15, 2018PFIZER -

Patent Citations (39) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0320308
DESCRIPTIONUS2006034826
DESCRIPTIONUS2006210567
DESCRIPTIONUS3625214
DESCRIPTIONUS4036945
DESCRIPTIONUS4331647
DESCRIPTIONUS4458066
DESCRIPTIONUS4789734
DESCRIPTIONUS4925673
DESCRIPTIONUS4946778
DESCRIPTIONUS5091309
DESCRIPTIONUS5223409
DESCRIPTIONUS5427930
DESCRIPTIONUS5585089
DESCRIPTIONUS5698520
DESCRIPTIONUS5744311
DESCRIPTIONUS5954687
DESCRIPTIONUS6025134
DESCRIPTIONUS6027889
DESCRIPTIONUS6033881
DESCRIPTIONUS6165460
DESCRIPTIONUS6368832
DESCRIPTIONUS6579854
DESCRIPTIONUS6808710
DESCRIPTIONUS6998252
DESCRIPTIONWO8907136
DESCRIPTIONWO9001069
DESCRIPTIONWO9002809
DESCRIPTIONWO9117271
DESCRIPTIONWO9201047
DESCRIPTIONWO9209690
DESCRIPTIONWO9215679
DESCRIPTIONWO9218619
DESCRIPTIONWO9220791
DESCRIPTIONWO9301288
OPPOSITIONWO02086083
OPPOSITIONWO2006121168
OPPOSITIONWO2006133396
SEARCHWO2006133396

Non-Patent Literature (NPL) Citations (170) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- AGATA ET AL., INT. IMMUNOL., (1996), vol. 8, page 765-
DESCRIPTION- AHMED ET AL., J. VIROL., (1984), vol. 51, pages 34 - 41-
DESCRIPTION- APPAY ET AL., JEXP MED, (2000), vol. 192, pages 63 - 75-
DESCRIPTION- ARKIN; YOUVAN, PROC. NATL. ACAD. SCI. USA, (1992), vol. 89, pages 7811 - 7815-
DESCRIPTION- BACHMANN ET AL., J IMMUNOL, (2005), vol. 175, pages 4686 - 96-
DESCRIPTION- BARANY; MERRIFIELD, THE PEPTIDES: ANALYSIS, SYNTHESIS, BIOLOGY. VOL. 2: SPECIAL METHODS IN PEPTIDE SYNTHESIS, PART A, vol. 2, pages 3 - 284-
DESCRIPTION- BARBAS ET AL., PROC. NATL. ACAD. SCI. USA, (1991), vol. 88, pages 7978 - 7982-
DESCRIPTION- BARBER ET AL., NATURE, (2006), vol. 439, page 682-
DESCRIPTION- BAROUCH ET AL., SCIENCE, (2000), vol. 290, pages 486 - 92-
DESCRIPTION- BEAUCAGE; CARUTHERS, TETRA. LETTS., (1981), vol. 22, no. 20, pages 1859 - 1862-
DESCRIPTION- BEAUCAGE ET AL., TETRA. LETT., (1981), vol. 22, pages 1859 - 1862-
DESCRIPTION- BERGER; KIMMEL, Methods in Enzymology, Volume 152, Guide to Molecular Cloning Techniques, ACADEMIC PRESS, INC., (1987), vol. 152-
DESCRIPTION- BERKNER, CUR. TOP. MICROBIOL. IMMUNOL., (1992), vol. 158, pages 39 - 6-
DESCRIPTION- BERLINER ET AL., BIO TECHNIQUES, (1988), vol. 6, pages 616 - 629-
DESCRIPTION- BERNSTEIN ET AL., NATURE, (2001), vol. 409, pages 363 - 366-
DESCRIPTION- BERZOFSKY ET AL., J. CLIN. INVEST., (2004), vol. 114, pages 456 - 462-
DESCRIPTION- BIRD ET AL., SCIENCE, (1988), vol. 242, page 423-
DESCRIPTION- BITTER ET AL., METHODS IN ENZYMOLOGY, (1987), vol. 153, pages 516 - 544-
DESCRIPTION- BOETTLER ET AL., J VIROL, (2006), vol. 80, pages 3532 - 40-
DESCRIPTION- BOUTBOUL ET AL., AIDS, (2005), vol. 19, pages 1981 - 6-
DESCRIPTION- BRANDYOPADHYAY ET AL., MOL. CELL BIOL., (1984), vol. 4, pages 749 - 754-
DESCRIPTION- BREAKFIELD ET AL., MOL. NEUROBIOL., (1987), vol. 1, pages 337 - 371-
DESCRIPTION- BROWN ET AL., J. IMMUNOL., (1981), vol. 127, pages 539 - 46-
DESCRIPTION- BROWN ET AL., METH. ENZYMOL., (1979), vol. 68, pages 109 - 151-
DESCRIPTION- BROWN ET AL., NATURE, (1993), vol. 364, page 33-
DESCRIPTION- BUCHNER ET AL., ANAL. BIOCHEM., (1992), vol. 205, pages 263 - 270-
DESCRIPTION- BUCHSCHALCHER ET AL., J. VIROL., (1992), vol. 66, pages 2731 - 2739-
DESCRIPTION- CARTER ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1992), vol. 89, page 4285-
DESCRIPTION- CASIMIRO ET AL., J VIROL, (2005), vol. 79, pages 15547 - 55-
DESCRIPTION- CECH, J., AMER. MED. ASSN., (1988), vol. 260, page 3030-
DESCRIPTION- CHEN ET AL., CYTOTHERAPY, (2002), vol. 4, pages 41 - 8-
DESCRIPTION- COLE ET AL., Monoclonal Antibodies and Cancer Therapy, ALAN R. LISS, INC., (1985), page 77 96-
DESCRIPTION- COLIGAN ET AL., METHODS IN ENZYMOLOGY, pages 2.8.1 - 2.8.10-
DESCRIPTION- DELAGRAVE ET AL., PROTEIN ENG., (1993), vol. 6, no. 3, page 327 331-
DESCRIPTION- DONG ET AL., NATURE, (1999), vol. 5, pages 1365 - 1369-
DESCRIPTION- DORFMAN ET AL., AM. J. SURG. PATHOL., (2006), vol. 30, pages 802 - 810-
DESCRIPTION- EDELMAN ET AL., Methods in Enzymology, ACADEMIC PRESS, (1967), vol. 1, page 422-
DESCRIPTION- ENGELHARD, CURR. OPIN. IMMUNOL., (1994), vol. 6, page 13-
DESCRIPTION- FINK ET AL., HUM. GENE THER., (1992), vol. 3, pages 11 - 19-
DESCRIPTION- FREMONT ET AL., IMMUNITY, (1998), vol. 8, page 305-
DESCRIPTION- FRESSE ET AL., BIOCHEM. PHARMACOL., (1990), vol. 40, pages 2189 - 2199-
DESCRIPTION- FROLOV ET AL., PROC. NATL. ACAD. SCI. USA, (1996), vol. 93, pages 11371 - 11377-
DESCRIPTION- FULLER ET AL., J IMMUNOL, (2005), vol. 174, pages 5926 - 30-
DESCRIPTION- GAGLIARDI ET AL., INT. IMMUNOL., (1995), vol. 7, pages 1741 - 52-
DESCRIPTION- GEFTER, M. L. ET AL., SOMATIC CELL GENET., (1977), vol. 3, pages 231 - 36-
DESCRIPTION- GORZIGLIA ET AL., J. VIROL., (1992), vol. 66, pages 4407 - 4412-
DESCRIPTION- HARARI ET AL., BLOOD, (2004), vol. 103, pages 966 - 72-
DESCRIPTION- HASSELHOFF, NATURE, (1988), vol. 334, page 585-
DESCRIPTION- HELENE, C., ANTICANCER DRUG DESIGN, (1991), vol. 6, no. 6, page 569-
DESCRIPTION- H. HERWEIJER ET AL., HUMAN GENE THERAPY, (1995), vol. 6, pages 1161 - 1167-
DESCRIPTION- HOLLADAY ET AL., TETRAHEDRON LETT., (1983), vol. 24, pages 4401 - 4404-
DESCRIPTION- HOOGENBOOM ET AL., NUCLEIC ACIDS RES., (1991), vol. 19, pages 4133 - 4137-
DESCRIPTION- HUDSON ET AL., INT. J. PEPT. PROT. RES., (1979), vol. 14, page 177 185-
DESCRIPTION- HUSE ET AL., SCIENCE, (1989), vol. 246, page 1275-
DESCRIPTION- IBEGBU ET AL., J IMMUNOL., (2005), vol. 174, pages 6088 - 6094-
DESCRIPTION- I. FROLOV ET AL., PROC. NATL. ACAD. SCI. USA, (1996), vol. 93, pages 11371 - 11377-
DESCRIPTION- ISHIDA ET AL., EMBO J., (1992), vol. 11, page 3887-
DESCRIPTION- ISHIDA ET AL., EMBO J., (1992), vol. 11, pages 3887 - 3895-
DESCRIPTION- ITAKURA ET AL., ANNU. REV. BIOCHEM., (1984), vol. 53, page 323-
DESCRIPTION- ITAKURA ET AL., SCIENCE, (1984), vol. 198, page 1056-
DESCRIPTION- JOHNSON ET AL., J. VIROL., (1992), vol. 66, page 29522965-
DESCRIPTION- JOLIOT ET AL., PROC NATL ACAD SCI USA, (1991), vol. 88, pages 1864 - 1868-
DESCRIPTION- JONES, CURR. OPIN. IMMUNOL., (1997), vol. 9, page 75-
DESCRIPTION- JONES ET AL., NATURE, (1986), vol. 321, page 522-
DESCRIPTION- KAECH ET AL., CELL, (2002), vol. 111, pages 837 - 51-
DESCRIPTION- KAECH ET AL., NAT IMMUNOL, (2003), vol. 4, pages 1191 - 8-
DESCRIPTION- KAISER ET AL., SCIENCE, (1989), vol. 243, page 187-
DESCRIPTION- KENT, ANNU. REV. BIOCHEM., (1988), vol. 57, page 957-
DESCRIPTION- KOHLER; MILSTEIN, NATURE, (1995), vol. 256, pages 495 - 49-
DESCRIPTION- KOTIN ET AL., PROC. NATL. ACAD. SCI. USA, (1990), vol. 87, pages 2211 - 2215-
DESCRIPTION- KOZBOR ET AL., IMMUNOL. TODAY, (1983), vol. 4, page 72-
DESCRIPTION- LANG ET AL., EUR J IMMUNOL, (2005), vol. 35, pages 738 - 45-
DESCRIPTION- LERNER, E. A., YALE J. BIOL. MED., (1981), vol. 54, pages 387 - 402-
DESCRIPTION- LU ET AL., Abstracts of the Meeting on Gene Therapy, COLD SPRING HARBOR LABORATORY, (19920922), page 66-
DESCRIPTION- MACKETT ET AL., BIOTECHNOLOGY, (1992), vol. 24, pages 495 - 499-
DESCRIPTION- MADDEN, ANNU. REV. IMMUNOL., (1995), vol. 13, page 587-
DESCRIPTION- MADZAK ET AL., J. GEN. VIROL., (1992), vol. 73, page 15331536-
DESCRIPTION- MAHER ET AL., ANTISENSE RES. AND DEV., (1991), vol. 1, no. 3, page 227-
DESCRIPTION- MANN ET AL., J. VIROL., (1985), vol. 54, pages 401 - 407-
DESCRIPTION- MARCUS-SAKURA, ANAL. BIOCHEM., (1988), vol. 172, page 289-
DESCRIPTION- MARGOLSKEE, CURR. TOP. MICROBIOL. IMMUNOL., (1992), vol. 158, pages 67 - 90-
DESCRIPTION- MELENHORST ET AL., BLOOD, (2005), vol. 106, page 671A-
DESCRIPTION- MELENHORST ET AL., CYTOTHERAPY, (2005), vol. 7, no. L-
DESCRIPTION- MERRIFIELD ET AL., J. AM. CHEM. SOC., (1963), vol. 85, pages 2149 - 2156-
DESCRIPTION- MERRIFIELD, SCIENCE, (1986), vol. 232, page 342-
DESCRIPTION- MIGUELES ET AL., NAT IMMUNOL, (2002), vol. 3, pages 1061 - 8-
DESCRIPTION- MILLER, CURR. TOP. MICROBIOL. IMMUNOL., (1992), vol. 158, pages 1 - 24-
DESCRIPTION- MILLER ET AL., MOL. CELL BIOL., (1985), vol. 5, pages 431 - 437-
DESCRIPTION- MORLEY, TRENDS PHARM. SCI., (1980), page 463 468-
DESCRIPTION- MORSEY ET AL., CELL. BIOCHEM., (1993), vol. 17E-
DESCRIPTION- MUZYCZKA, CURR. TOP. MICROBIOL. IMMUNOL., (1992), vol. 158, pages 91 - 123-
DESCRIPTION- NARANG ET AL., METH. ENZYMOL., (1979), vol. 68, pages 90 - 99-
DESCRIPTION- NARANG ET AL., TETRAHEDRON, (1983), vol. 39, no. 3-
DESCRIPTION- NATURE, (2005), vol. 436, page 578-
DESCRIPTION- NEEDHAM-VANDEVANTER ET AL., NUCL. ACIDS RES., (1984), vol. 12, pages 6159 - 6168-
DESCRIPTION- NISHIMURA ET AL., INT. IMMUNOL., (1996), vol. 8, page 773-
DESCRIPTION- NISONHOFF ET AL., ARCH. BIOCHEM. BIOPHYS., (1960), vol. 89, page 230-
DESCRIPTION- NOVELLINO ET AL., CANCER IMMUNOL. IMMUNOTHER, (2005), vol. 54, no. 3, pages 187 - 207-
DESCRIPTION- ON ET AL., GENE, (1990), vol. 89, pages 279 - 282-
DESCRIPTION- PACK ET AL., BIO/TECHNOLOGY, (1993), vol. 11, page 1271-
DESCRIPTION- PAGE ET AL., J. VIROL., (1990), vol. 64, pages 5370 - 5276-
DESCRIPTION- PETROPOUPLOS ET AL., J. VIROL., (1992), vol. 66, pages 3391 - 3397-
DESCRIPTION- PLUCKTHUN, BIOTECHNOLOGY, (1991), vol. 9, page 545-
DESCRIPTION- PORTER, BIOCHEM. J., (1959), vol. 73, page 119-
DESCRIPTION- QIN ET AL., ACTA PHARMACOL. SIN., (2002), vol. 23, no. 6, pages 534 - 8-
DESCRIPTION- QUANTIN ET AL., PROC. NAD. ACAD. SCI. USA, (1992), vol. 89, pages 2581 - 2584-
DESCRIPTION- RAMMENSEE ET AL., IMMUNOGENETICS, (1995), vol. 41, page 178-
DESCRIPTION- RAMMENSEE ET AL., J. CURR. OPIN. IMMUNOL., (1998), vol. 10, page 478-
DESCRIPTION- RIECHMANN ET AL., NATURE, (1988), vol. 332, page 323-
DESCRIPTION- ROSENBERG ET AL., N. ENG. J. MED., (1990), vol. 323, no. 9, pages 570 - 578-
DESCRIPTION- ROSENFELD ET AL., CELL, (1992), vol. 68, pages 143 - 155-
DESCRIPTION- SANDHU, CRIT. REV. BIOTECH., (1992), vol. 12, page 437-
DESCRIPTION- SAXENA ET AL., BIOCHEMISTRY, (1970), vol. 9, pages 5015 - 5021-
DESCRIPTION- SETTE; GREY, CURR. OPIN. IMMUNOL., (1992), vol. 4, page 79-
DESCRIPTION- SHINOHARA ET AL., GENOMICS, (1994), vol. 23, page 704-
DESCRIPTION- SHINOHARA ET AL., GENOMICS, (1994), vol. 23, pages 704 - 706-
DESCRIPTION- SINGER ET AL., J. IMMUNOL., (1993), vol. 150, page 2844-
DESCRIPTION- SLAPAK; KUFE, Principles of Cancer Therapy, HARRISON'S PRINCIPLES OF INTERNAL MEDICINE-
DESCRIPTION- SMITH ET AL., IMMUNITY, (1996), vol. 4, page 203-
DESCRIPTION- SORGE ET AL., MOL. CELL BIOL., (1984), vol. 4, pages 1730 - 1737-
DESCRIPTION- SOUTHWOOD ET AL., J. IMMUNOL., (1998), vol. 160, page 3363-
DESCRIPTION- SPATOLA, LIFE SCI., (1986), vol. 38, pages 1243 - 1249-
DESCRIPTION- S. SCHLESINGER, TRENDS BIOTECHNOL., (1993), vol. 11, pages 18 - 22-
DESCRIPTION- STERN ET AL., STRUCTURE, (1994), vol. 2, page 245-
DESCRIPTION- STRATFORD-PERRICAUDET ET AL., HUM. GENE THER., (1990), vol. 1, pages 241 - 256-
DESCRIPTION- VERHOEYEN ET AL., SCIENCE, (1988), vol. 239, page 1534-
DESCRIPTION- VIVIER; DAERON, IMMUNOL. TODAY, (1997), vol. 18, page 286-
DESCRIPTION- WALKER ET AL., NATURE, (1987), vol. 328, pages 345 - 8-
DESCRIPTION- WARD ET AL., NATURE, (1989), vol. 341, page 544-
DESCRIPTION- WEINTRAUB, SCIENTIFIC AMERICAN, (1990), vol. 262, page 40-
DESCRIPTION- WESTON; PARISH, J IMMUNOL METHODS, (1990), vol. 133, pages 87 - 97-
DESCRIPTION- WHERRY ET AL., J. VIROL., (2003), vol. 77, pages 4911 - 27-
DESCRIPTION- WHITLOW ET AL., METHODS: A COMPANION TO METHODS IN ENZYMOLOGY, (1991), vol. 2, page 97-
DESCRIPTION- WILKINSON ET AL., NUCL. ACIDS RES., (1992), vol. 20, pages 2233 - 2239-
DESCRIPTION- WU ET AL., J. BIOL. CHEM., (1987), vol. 262, page 4429-
DESCRIPTION- YEH ET AL., PROC. NATL. ACAD. SCI., (1976), vol. 76, pages 2927 - 31-
DESCRIPTION- ZAJ ET AL., J EXP MED, (1998), vol. 188, pages 2205 - 13-
DESCRIPTION- ZAMORE, SCIENCE, (2002), vol. 296, pages 1265 - 1269-
EXAMINATION- Ahmed R., Biron C.A., "Immunity to Viruses", Ahmed R., Biron C.A., Paul W.E., Fundamental Immunology, Philadelphia, US, Lippincott-Raven Publishers, (1999), vol. 39, pages 1295 - 1334-
EXAMINATION- BECKER J C ET AL, "Tumor escape mechanisms from immuno-surveillance: Induction of unresponsiveness in a specific MHC-restricted CD4+ human T cell clone by the autologous MHC class II+ melanoma", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (199312), Database accession no. 7906140, URL: www.ncbi.nlm.nih.gov/pubmed, XP000938854-
EXAMINATION- HIRANO FUMIYA ET AL, "Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, (20050201), vol. 65, no. 3, ISSN 0008-5472, pages 1089 - 1096, XP002419626-
EXAMINATION- LISA BORKNER ET AL, "RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, (20100327), vol. 59, no. 8, ISSN 1432-0851, pages 1173 - 1183, XP019842188-
EXAMINATION- PENG WEIYI ET AL, "Blockade of the PD-1 pathway enhances the efficacy of adoptive cell therapy against cancer", ONCOIMMUNOLOGY, (201302), vol. 2, no. 2, page e22691-
EXAMINATION- PILON-THOMAS SHARI ET AL, "Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 APR 2010 LNKD- PUBMED:20194714, (20100401), vol. 184, no. 7, ISSN 1550-6606, pages 3442 - 3449-
EXAMINATION- STEINBRINK K ET AL, "Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific energy in CD8+ T cells resulting in a failure to lyse tumor cells", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (19990301), vol. 93, no. 5, ISSN 0006-4971, pages 1634 - 1642, XP002954809-
EXAMINATION- LÃœSCHER U ET AL, "The pattern of cytokine gene expression in freshly excised human metastatic melanoma suggests a state of reversible anergy of tumor-infiltrating lymphocytes.", MEDLINE, US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US, (19940515), Database accession no. NLM8181865, URL: www.ncbi.nlm.nih.gov/pubmed, XP002948050
EXAMINATION- F. Wei ET AL, "Strength of PD-1 signaling differentially affects T-cell effector functions", Proceedings of the National Academy of Sciences, (20130702), vol. 110, no. 27, doi:10.1073/pnas.1305394110, ISSN 0027-8424, pages E2480 - E2489, XP055142199
EXAMINATION- YEE C ET AL, "Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, (20021210), vol. 99, no. 25, doi:10.1073/PNAS.242600099, ISSN 0027-8424, pages 16168 - 16173, XP002505178
EXAMINATION- YOSHIKO IWAI ET AL, "PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells.", INTERNATIONAL IMMUNOLOGY, (20041220), vol. 17, no. 2, doi:dxh194, ISSN 0953-8178, pages 133 - 144, XP055142463
OPPOSITION- HIRANO et al., "Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity", Cancer Research, (20050201), vol. 65, no. 3, pages 1089 - 1096, XP002419626-
OPPOSITION- OVERWIJK et al., Current Protocols in Immunology, (20000000), vol. supp. 39, pages 20.1.1 - 20.1.29, XP055469239-
OPPOSITION- STROME et al., "B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma", Cancer Research, (20031001), vol. 63, pages 6501 - 6505, XP002487684-
OPPOSITION- BLANK et al., "Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro", International Journal of Cancer, (20060000), vol. 119, pages 317 - 327, XP002557386
OPPOSITION- BLANK et al., "Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy", Cancer immunology, Immunotherapy, (20050000), vol. 54, pages 307 - 314, XP002419627
OPPOSITION- BLANK et al., "Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion", Cancer immunology, Immunotherapy, (20070000), vol. 56, pages 739 - 745, XP002497527
OPPOSITION- SCHIETINGER et al., "Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis /HHS Author Manuscript/", PMC, (20170816), pages 1 - 26, XP055617045
OPPOSITION- BARBER et al., "Restoring function in exhausted CD8 T cells during chronic viral infection", Nature, (20060209), vol. 439, pages 682 - 687, XP002419629
OPPOSITION- DONG et al., "Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion", Nature medicine, (20020800), vol. 8, no. 8, pages 793 - 800, XP002397368
OPPOSITION- CURIEL et al., "Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity", Nature medicine, (20030500), vol. 9, no. 5, pages 562 - 567, XP002311470
OPPOSITION- YEE et al., "Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells", PNAS, (20021210), vol. 99, no. 25, pages 16168 - 16173, XP002505178
OPPOSITION- IWAI et al., "PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells", International immunology, (20041220), vol. 17, no. 2, pages 133 - 144, XP055142463
OPPOSITION- BLANK et al., "PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells", Cancer research, (20040201), vol. 64, pages 1140 - 1145, XP002411529
SEARCH- STROME SCOTT E ET AL, "B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma.", CANCER RESEARCH, (20031001), vol. 63, no. 19, ISSN 0008-5472, pages 6501 - 6505, XP002487684 [X] 1-15 * the whole document *-
SEARCH- WEBSTER W SCOTT ET AL, "Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 SEP 2007, (20070901), vol. 179, no. 5, ISSN 0022-1767, pages 2860 - 2869, XP002557388 [XP] 1-15 * page 2864, column r - page 2865, column l, paragraph 2; figure 3B *-
SEARCH- BLANK CHRISTIAN ET AL, "Blockade of PD-L1 (B7-H1) augments human tumor-specific T cell responses in vitro", INTERNATIONAL JOURNAL OF CANCER, (200607), vol. 119, no. 2, ISSN 0020-7136, pages 317 - 327, XP002557386 [X] 1-15 * abstract * * page 320, column r, paragraph l - page 325; figures 5, 6 *
SEARCH- CHRISTIAN BLANK ET AL, "Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, (20050401), vol. 54, no. 4, ISSN 1432-0851, pages 307 - 314, XP019333106 [X] 1-15 * abstract * * page 311, column R, paragraph 2 - page 312 *
SEARCH- YEE CASSIAN, "Adoptive T-cell therapy of cancer", HEMATOLOGY - ONCOLOGY CLINICS OF NORTH AMERICA, W.B. SAUNDERS, US, (20060601), vol. 20, no. 3, ISSN 0889-8588, pages 711 - 733, XP008093818 [Y] 1-15 * the whole document *
SEARCH- RILEY ET AL, "The road to recovery: translating PD-1 biology into clinical benefit", TRENDS IN IMMUNOLOGY, ELSEVIER, RAHWAY, NJ, US, (20061222), vol. 28, no. 2, ISSN 1471-4906, pages 48 - 50, XP005867493 [Y] 1-15 * the whole document *
SEARCH- CURIEL T J ET AL, "Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, (20030501), vol. 9, no. 5, ISSN 1078-8956, pages 562 - 567, XP002311470 [X] 1-15 * the whole document *
SEARCH- KNUTSON K L ET AL, "ADOPTIVE T-CELL THERAPY FOR THE TREATMENT OF SOLID TUMOURS", EXPERT OPINION ON BIOLOGICAL THERAPY, ASHLEY, LONDON, GB, (20020101), vol. 2, no. 1, ISSN 1471-2598, pages 55 - 66, XP009043879 [Y] 1-15 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents